Research programme: anticancer antibodies - GammaCan

Drug Profile

Research programme: anticancer antibodies - GammaCan

Alternative Names: VitiGam; Vitiligo-derived-immunoglobulin-G

Latest Information Update: 13 Sep 2015

Price : $50

At a glance

  • Originator GammaCan International
  • Class Immunoglobulins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Malignant melanoma

Most Recent Events

  • 12 Aug 2008 Preclinical development is ongoing
  • 12 Aug 2008 Pharmacodynamics data from a meta-analysis of Preclinical trials in Malignant melanoma released by GammaCan
  • 11 Mar 2008 Pharmacodynamics data from preclinical studies in Malignant melanoma released by GammaCan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top